Press Releases

AdvaMedDx Names Quidel’s Doug Bryant as New Board Chair

WASHINGTON, D.C. – AdvaMedDx, a division of the Advanced Medical Technology Association (AdvaMed) that focuses on the value diagnostics bring to patients’ health and health care, while addressing the need for regulatory modernization of the innovative companies that develop and manufacture diagnostic tests, has elected Doug Bryant, president and CEO of Quidel Corporation, as its new Board chair. 

“We are thrilled Doug will be furthering our efforts to highlight and leverage the value of diagnostics, advocating for policies that advance innovation, and the safe, effective use of tests that are critical to high-quality patient care and public health,” said Susan Van Meter, AdvaMedDx executive director. “Doug’s extensive experience within the industry, domestically and globally, his status as a founding member of AdvaMedDx and his stature among his peers provide him a wealth of knowledge and relationships as he works to help shape our strategies and objectives.” 

Bryant brings more than three decades of experience in the diagnostics and medical device industry. He joined Quidel in 2009 as president and CEO. Prior to joining Quidel, Mr. Bryant served as executive vice president and chief operating officer at Luminex Corporation. From 1983 to 2007, he held various worldwide commercial operations positions with Abbott Laboratories as vice president of Abbott Vascular for Asia/Japan, vice president of Abbott Molecular Global Commercial Operations and vice president of Abbott Diagnostics Global Commercial Operations, among other positions. 

“AdvaMedDx is comprised of the world’s leading diagnostic manufacturers. As chairman, I look forward to working with the Board of Directors and member companies to advocate for policies that recognize the value of diagnostics and the key role they play in generating new discoveries and fostering better care for patients,” said Bryant. “I am proud to have this opportunity to represent our industry that is shaped by innovation and powered through smart advocacy and collaborative policy development that supports the adoption of new, safe and effective diagnostic tests.” 

For more information, please contact: 

Elyse Petroni 
[email protected] 
(202) 434-7271